Log in
NASDAQ:VRTX

Vertex Pharmaceuticals Stock Forecast, Price & News

$226.71
+8.61 (+3.95 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$219.61
Now: $226.71
$226.72
50-Day Range
$207.01
MA: $223.53
$276.09
52-Week Range
$197.47
Now: $226.71
$306.08
Volume1.05 million shs
Average Volume1.85 million shs
Market Capitalization$58.95 billion
P/E Ratio28.63
Dividend YieldN/A
Beta0.79
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More
Vertex Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100
Employees3,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 billion
Cash Flow$4.90 per share
Book Value$23.66 per share

Profitability

Net Income$1.18 billion

Miscellaneous

Market Cap$58.95 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$226.71
+8.61 (+3.95 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

How has Vertex Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRTX shares have increased by 2.9% and is now trading at $226.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vertex Pharmaceuticals?

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 8 hold ratings, 22 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vertex Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vertex Pharmaceuticals?

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Vertex Pharmaceuticals
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Thursday, October, 29th. The pharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.68. The pharmaceutical company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.48 billion. Vertex Pharmaceuticals had a return on equity of 28.55% and a net margin of 38.51%. The business's revenue for the quarter was up 61.9% on a year-over-year basis. During the same period last year, the company earned $1.23 EPS.
View Vertex Pharmaceuticals' earnings history
.

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals declared that its Board of Directors has approved a share repurchase plan on Wednesday, July 31st 2019, which authorizes the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board believes its shares are undervalued.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6-6.2 billion, compared to the consensus revenue estimate of $6.02 billion.

What price target have analysts set for VRTX?

31 analysts have issued 1 year target prices for Vertex Pharmaceuticals' stock. Their forecasts range from $230.00 to $340.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $290.59 in the next year. This suggests a possible upside of 28.2% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Dr. Jeffrey Marc Leiden, Exec. Chairman (Age 64, Pay $4.88M)
  • Dr. Reshma Kewalramani, CEO, Pres & Director (Age 47, Pay $2.03M)
  • Mr. Charles F. Wagner Jr., Exec. VP & CFO (Age 52, Pay $1.66M)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Patient Officer (Age 52, Pay $1.41M)
  • Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 54, Pay $2.07M)
  • Mr. Paul M. Silva, Sr. VP & Corp. Controller (Age 54, Pay $833.97k)
  • Dr. David M. Altshuler, Exec. VP of Global Research & Chief Scientific Officer (Age 55)
  • Mr. Mike Tirozzi, SVP and Chief Information & Data Officer
  • Mr. Michael J. Parini, Exec. VP & Chief Admin., Legal and Bus. Devel. Officer (Age 45)
  • Mr. Michael Partridge, Sr. VP of Investor Relations

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.68%), State Street Corp (4.37%), Jennison Associates LLC (1.39%), Nuveen Asset Management LLC (1.35%), JPMorgan Chase & Co. (0.86%) and California Public Employees Retirement System (0.83%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals
.

Which institutional investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., State Street Corp, AXA S.A., Banco Santander S.A., NN Investment Partners Holdings N.V., DE Burlo Group Inc., and Wells Fargo & Company MN. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young, and Yuchun Lee.
View insider buying and selling activity for Vertex Pharmaceuticals
.

Which institutional investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, Swiss National Bank, CIBC Private Wealth Group LLC, DekaBank Deutsche Girozentrale, Point72 Asset Management L.P., LA Financiere DE L Echiquier, PGGM Investments, and ARK Investment Management LLC.
View insider buying and selling activity for Vertex Pharmaceuticals
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $226.71.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $58.95 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.